Depo-Provera Lawsuit Statute of Limitations: How Long Do You Have to File?

Why Filing Deadlines Matter in the Depo-Provera Lawsuit

Tens of thousands of women in the United States used Depo-Provera (medroxyprogesterone acetate) for years — often as their primary contraceptive — without knowing that prolonged use could dramatically increase the risk of developing a meningioma, a brain tumor that grows on the lining of the brain or spinal cord. Many of those women were later diagnosed with meningiomas and underwent surgery, radiation, or both. Some sustained permanent neurological damage. And most had no idea the drug was connected to their diagnosis.

That is not an accusation of carelessness. It is a reflection of the science: the peer-reviewed evidence establishing a strong statistical link between long-term Depo-Provera use and meningioma was not published until March 27, 2024, when a landmark study appeared in the British Medical Journal. The FDA did not formally require a meningioma warning on Depo-Provera's label until December 17, 2025.

This timeline creates a profound legal question that sits at the center of the Depo-Provera litigation: if women could not reasonably have known their injury was caused by the drug until 2024 or later, does the statute of limitations clock start from their diagnosis — or from when that link became publicly known?

The answer to that question could determine whether thousands of women can file lawsuits at all. As of April 2026, MDL No. 3140 contains approximately 3,490 filed cases, with an estimated 10,000 additional claims held in reserve pending a key preemption ruling. Behind those numbers are real people navigating a legal system with hard deadlines that do not bend for ignorance of a connection that was unknowable until recently.

This guide explains exactly how those deadlines work, how the discovery rule applies to Depo-Provera plaintiffs, and what you should do if you believe you have a claim.

What Is a Statute of Limitations?

A statute of limitations is a state law that sets the maximum amount of time a person has to file a civil lawsuit after an injury or harm occurs. Every state has one. They vary in length, in how they are calculated, and in what exceptions apply.

The Consequence of Missing the Deadline

Missing the statute of limitations is permanent. A court will dismiss your lawsuit at the defendant's motion — regardless of how strong your evidence is, how severe your injuries were, or how much Pfizer knew and failed to disclose. There is no grace period. One day late is too late.

This is not a technicality. Courts enforce statutes of limitations strictly because they serve important policy purposes: evidence degrades over time, witnesses' memories fade, and defendants deserve some degree of finality rather than facing lawsuits over events from decades past.

Why It Is Not Automatic

The good news is that statutes of limitations are not always as rigid as they first appear. Several legal doctrines can delay when the clock starts, pause it while it is running, or reset it entirely. The most important of these for Depo-Provera plaintiffs is the discovery rule — described in detail in the next section. Tolling doctrines (addressed in Section 5) can also extend your deadline under specific circumstances. These doctrines do not apply automatically; they must be raised affirmatively by your attorney. But they are real legal tools that have helped plaintiffs in similar situations file timely claims years after a standard deadline might have expired.

The Discovery Rule — The Most Important Concept for Depo-Provera Plaintiffs

In most states, the statute of limitations for a product liability claim does not start running when the injury physically occurs. It starts when the plaintiff knew or reasonably should have known that the injury was caused by the product. This is called the discovery rule, and it is the single most important legal concept for Depo-Provera plaintiffs to understand.

How the Standard Rule Works

Under a pure discovery rule, the question is not "when were you diagnosed?" It is "when did you know — or when should a reasonable person in your position have known — that Depo-Provera caused your meningioma?" A woman who was diagnosed with a meningioma in 2019 but had no reason to connect it to her Depo-Provera injections would not necessarily have started her limitations clock in 2019.

The Critical Application to Depo-Provera

Here is why this matters so much in these cases: the scientific community did not establish a strong, peer-reviewed link between long-term Depo-Provera use and meningioma until March 27, 2024, when a study in the British Medical Journal reported a 5.6-fold increase in meningioma risk among women with the most prolonged exposure. Before that date, there was no reliable public evidence that a reasonable patient or physician could have used to connect a meningioma diagnosis to Depo-Provera use.

The FDA reinforced this timeline when it approved a formal meningioma warning for Depo-Provera labels on December 17, 2025 — approximately 21 months after the BMJ publication. This was the first time the connection received official regulatory acknowledgment in the United States.

Plaintiff attorneys argue — and courts in mass tort cases have accepted similar arguments — that a reasonable person could not have known their meningioma was linked to Depo-Provera before March 2024. Under this argument, the statute of limitations clock for most Depo-Provera plaintiffs arguably started in March 2024 (or December 2025, depending on which event a court finds most significant), even if their diagnosis and drug use occurred years earlier.

State-by-State Statute of Limitations (All 50 States)

The table below lists the standard product liability statute of limitations for all 50 states. The "Discovery Rule Start" column shows the approximate deadline if a court accepts that the clock began in March 2024 (BMJ publication date). The urgency rating reflects risk under that analysis.

Important: These deadlines are general guidelines only. Actual deadlines depend on when your specific clock began, which tolling doctrines apply, and your state's current case law. Filing in the MDL does not replace state-law compliance. Consult a licensed attorney for advice specific to your situation.

MDL Note: The Depo-Provera litigation is centralized in MDL No. 3140 before Judge M. Casey Rodgers in the Northern District of Florida. Filing in the federal MDL does not change your state law statute of limitations. Plaintiffs must comply with their own state's deadline; the MDL provides a coordinated venue for pretrial proceedings, not a deadline extension.

What Tolls (Pauses) the Statute of Limitations

Beyond the discovery rule, several additional legal doctrines can pause or extend the statute of limitations clock. These are called "tolling" doctrines.

Three Real-World Scenarios with Analysis

Abstract legal rules are easier to understand when applied to concrete situations. These hypothetical scenarios illustrate how the statute of limitations analysis works in practice.

What If Your Deadline Has Already Passed?

If a straightforward reading of your state's statute of limitations suggests your deadline may have passed, do not assume your claim is gone. Here is what actually happens when this issue arises:

Attorneys argue the discovery rule and fraudulent concealment in motions. If Pfizer files a motion to dismiss your claim on statute of limitations grounds, your attorney will argue in opposition that the clock did not start until 2024 or 2025 under the discovery rule, and that fraudulent concealment further tolled the limitations period. The court then decides — and the outcome can vary by jurisdiction and by the specific facts of your case.

Courts can and do reach different conclusions. In mass tort litigation, courts in different jurisdictions handle these arguments differently. Some courts have been receptive to expansive discovery rule arguments; others apply stricter standards. This is another reason to consult an experienced mass tort attorney rather than making assumptions.

Filing preserves your rights while the legal argument is made. Even if there is uncertainty about whether your claim is timely, filing a complaint in the MDL at least gives your attorney the opportunity to make these arguments. Not filing forfeits those rights permanently — there is no argument to make if no claim has been filed.

The bottom line: if you believe you have a claim but worry your time has passed, the answer is still to speak with an attorney immediately. The only way to know for certain whether you have a path forward is through a legal assessment of your specific facts — and that assessment is free.

Steps to Take Right Now

If you used Depo-Provera for 12 months or more and were diagnosed with a meningioma, here is what to do without delay.

Why Filing Sooner Is Better — Even When You Have Time

Even if you are confident your filing window remains open, waiting until the deadline approaches creates unnecessary risk and disadvantage. Here is why early filing benefits you:

• check_circle

  Medical records are more accessible now

  Healthcare providers typically retain records for 7 to 10 years, but electronic health records systems change and hospitals merge. The longer you wait, the higher the risk that critical records become unavailable or require expensive retrieval processes.

• check_circle

  Witnesses remember more clearly today

  Treating physicians, prescribing providers, and others whose testimony may support your case remember events more accurately the sooner they are asked about them.

• check_circle

  Attorneys build stronger cases with more lead time

  A case filed 18 months before a deadline gives your legal team time for thorough preparation, expert retention, and careful case strategy. A case filed three weeks before the deadline forces shortcuts.

• check_circle

  Early filers may have procedural advantages in the MDL

  In MDL proceedings, early-filed cases are often considered first for bellwether trial selection. Bellwether trials set the settlement value framework for all cases — being among the early filers positions you at the front of that process.

• check_circle

  The preemption ruling could trigger a wave of filings

  Approximately 10,000 warehoused claims are expected to file in the MDL immediately after a favorable preemption ruling. When that wave hits, courts and law firms will be strained. Cases already filed and developed will move more smoothly through that environment than newly filed cases scrambling for attention.

Frequently Asked Questions

References

• 1. Dogu O, et al. “Meningioma risk and prolonged use of medroxyprogesterone acetate: a nationwide case-control study.” British Medical Journal. March 27, 2024.
• 2. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA approves labeling updates for medroxyprogesterone acetate contraceptive injections regarding meningioma risk. December 17, 2025.
• 3. In re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, N.D. Fla. (Judge M. Casey Rodgers).
• 4. Blonski v. Pfizer Inc., Case No. 3:24-cv-00512, N.D. Fla. (Bellwether Trial scheduled December 7–14, 2026).
• 5. PACER case count data, MDL No. 3140, April 2026 (approximately 3,490 member cases).
• 6. Restatement (Second) of Torts § 899 (discovery rule in latent injury cases).
• 7. Servicemembers Civil Relief Act, 50 U.S.C. §§ 3901–4043 (military tolling provisions).